Show Summary Details
Page of

Peritoneal mesothelioma 

Peritoneal mesothelioma
Peritoneal mesothelioma

H. Richard Alexander

, Dario Baratti

, Terence C. Chua

, Marcello Deraco

, Raffit Hassan

, Marzia Pennati

, Federica Perrone

, Paul H. Sugarbaker

, Anish Thomas

, Keli Turner

, Tristan D. Yan

, and Nadia Zaffaroni


March 29, 2019: This chapter has been re-evaluated and remains up-to-date. No changes have been necessary.


Surgical technology for mesenteric cytoreduction has been explained in the text and illustrated in figures

Possible benefits for bidirectional adjuvant normothermic chemotherapy (BANC) provided with a projected 10-year survival of 64% in malignant peritoneal mesothelioma patients

Prognostic value of immunocytochemical assessment of Ki-67 presented as a means of identifying patients with a poor prognosis

Updated on 25 May 2017. The previous version of this content can be found here.
Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 13 July 2020

Malignant peritoneal mesothelioma (MPM) is a rare malignancy arising from the serosa of the abdominal cavity; its natural history is hallmarked by intra-abdominal disease progression. Peritoneal mesothelioma patients generally present with abdominal pain and/or ascites. Pathologically, a positive immunostain for calretinin has markedly increased the accuracy of diagnosis. A new staging system combining extent of tumour burden measured by the peritoneal cancer index (PCI), abdominal nodal status and extra-abdominal metastases has been demonstrated to reliably stratify patient outcomes after cytoreductive surgery (CRS) and hyperthermic perioperative chemotherapy (HIPEC). Over the past decade, the management of these patients has evolved as a multimodality treatment similar to ovarian cancer treatment and now involves CRS and HIPEC.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.